摘要
目的分析米非司酮辅助治疗子宫内膜异位症的效果及对血清性激素水平的影响。方法抽取2019年1月至2021年5月濮阳市妇幼保健院收治的子宫内膜异位症患者92例,按随机数字表法分为米非司酮组和孕三烯酮组,每组46例。孕三烯酮组予以常规治疗,米非司酮组在孕三烯酮组的基础上予以米非司酮治疗。比较两组疗效、症状恢复时间、血清性激素水平、子宫内膜厚度、炎性因子水平及不良反应发生率。结果米非司酮组总有效率(95.65%,44/46)高于孕三烯酮组(78.26%,36/46),P<0.05;米非司酮组月经周期恢复正常时间、月经量恢复正常时间、腹痛消失时间均短于孕三烯酮组(P均<0.05);治疗后,米非司酮组黄体生成素水平高于孕三烯酮组,卵泡刺激素水平低于孕三烯酮组(P<0.05);治疗后,米非司酮组子宫内膜厚度小于孕三烯酮组(P<0.05);治疗后,米非司酮组肿瘤坏死因子-α、白细胞介素-6水平均低于孕三烯酮组(P均<0.05)。米非司酮组不良反应发生率(6.52%,3/46)与孕三烯酮组(10.87%,5/46)比较差异未见统计学意义(P>0.05)。结论米非司酮辅助治疗子宫内膜异位症,可提高疗效,缩短症状缓解时间,降低子宫内膜厚度,改善血清性激素与炎性因子水平,且联合用药安全性良好。
Objective To analyze the effect of mifepristone in adjuvant treatment of endometriosis and its influence on serum sex hormone levels.Methods Ninety-two patients with endometriosis treated in Puyang Maternal and Child Health Hospital from January 2019 to May 2021 were selected and divided into the mifepristone group and the gestrinone group according to the random number table method,with 46 cases in each group.The gestrinone group was given routine treatment,and the mifepristone group was given mifepristone treatment based on the treatment of the gestrinone group.Efficacy,symptom recovery time,serum sex hormones levels,endometrial thickness,inflammatory factors levels and adverse reactions were compared between the two groups.Results The total effective rate in the mifepristone group was 95.65%(44/46),which was higher than the 78.26%(36/46)in the getrienone group(P<0.05).The recovery time of menstrual cycle,menstrual volume and abdominal pain in the mifepristone group were shorter than those in the gestrinone group(P<0.05).After treatment,the level of luteinizing hormone in the mifepristone group was higher than that in the gestrinone group,and the level of follicle stimulating hormone was lower than that in the gestrinone group(P<0.05).After treatment,the endometrial thickness of the mifepristone group was thinner than that of the gestrinone group(P<0.05).After treatment,the levels of tumor necrosis factor-αand interleukin-6 in the mifepristone group were lower than those in the gestrinone group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the mifepristone group(6.52%,3/46)and the gestrinone group(10.87%,5/46),P>0.05.Conclusions Mifepristone can improve the efficacy in adjuvant treatment of endometriosis,shorten the symptom relief time,reduce the endometrial thickness,improve the serum sex hormones and inflammatory factors levels,and the combined medication is safe.
作者
王红云
周传亚
赵虎
Wang Hongyun;Zhou Chuanya;Zhao Hu(Department of Postpartum Health Care,Puyang Maternal and Child Health Hospital,Puyang 457000,China;Department of GynecologyⅠ,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《中国实用医刊》
2022年第20期93-96,共4页
Chinese Journal of Practical Medicine
